){kind=logo}
Loeb & Loeb LLP is proud to sponsor ACI's 21st Annual Paragraph IV Disputes Conference taking place from April 29-30, 2025 where Co-Chair, Life Sciences, Jim Czaban will be speaking on the panel “Determining What is Listable in the Orange Book: What Can We Glean from the Latest FTC Activity on Drug Device Combinations, and Counterclaims?” on April 29, and Partner, Ryan Hagglund will be speaking on the panel "Examining How §112 Challenges are Playing Out in Hatch-Waxman Litigation: Key Takeaways for Brands and Generics" on April 30.
From the event website:
Leaders from both brand and generic drug companies recognize that this event is the single forum which serves both sides of the industry and is second to none in offering both legal and economic “take aways” for every sphere of this costly, complex and evolving litigation. This is the only event on market which not only addresses the hot topics but also puts them within the context of pre-suit considerations, case filings, final adjudication and every step in between. This unique dynamic exemplifies not only the importance of the content and legal theory presented, but the contending business acuities as well.
For more information, including how to register, please visit the event website.
From the event website:
Leaders from both brand and generic drug companies recognize that this event is the single forum which serves both sides of the industry and is second to none in offering both legal and economic “take aways” for every sphere of this costly, complex and evolving litigation. This is the only event on market which not only addresses the hot topics but also puts them within the context of pre-suit considerations, case filings, final adjudication and every step in between. This unique dynamic exemplifies not only the importance of the content and legal theory presented, but the contending business acuities as well.
For more information, including how to register, please visit the event website.
-
Partner -
Co-Chair, Life Sciences